News
AVXL
0.7194
-2.78%
-0.0206
Weekly Report: what happened at AVXL last week (1109-1113)?
Weekly Report · 3d ago
AVXL Deadline: AVXL Investors Have Opportunity to Lead Anavex Life Sciences Corp. Securities Fraud Lawsuit Filed by The Rosen Law Firm
PR Newswire · 11/11 00:29
What's Next for Anavex Life Sciences Corp. Shareholders After 6.35% Stock Drop? Glancy Prongay Wolke & Rotter LLP Explains Securities Fraud Class Action Lead Plaintiff Deadline
PR Newswire · 11/09 18:00
Weekly Report: what happened at AVXL last week (1102-1106)?
Weekly Report · 11/09 10:01
What Does Anavex Life Sciences Corp.'s 6.35% Stock Drop Mean for Investors? The Law Offices of Howard G. Smith Outlines Securities Fraud Class Action Lead Plaintiff Deadline
PR Newswire · 11/06 19:20
Anavex Deadline: AVXL Investors Have Opportunity to Lead Anavex Life Sciences Corp. Securities Fraud Lawsuit Filed by The Rosen Law Firm
PR Newswire · 11/05 23:15
What Should Anavex Life Sciences Corp. Investors Know After 6.35% Stock Drop? The Law Offices of Frank R. Cruz Outlines Securities Fraud Class Action Lead Plaintiff Deadline
PR Newswire · 11/05 18:50
Anavex Life Sciences Corp. Appoints Terrie Kellmeyer, Ph.D. as Chief Executive Officer and President
NASDAQ · 11/03 15:22
Anavex names interim chief Terrie Kellmeyer as permanent CEO
TipRanks · 11/03 14:15
Anavex Appoints Terrie Kellmeyer as President and CEO
TipRanks · 11/03 13:51
Anavex Life Sciences appoints Terrie Kellmeyer as CEO
Seeking Alpha · 11/03 13:17
Anavex Life Sciences Reconstitutes Board Committees After Director Resignations
TipRanks · 11/02 22:25
Weekly Report: what happened at AVXL last week (1026-1030)?
Weekly Report · 11/02 10:00
Anavex Deadline: AVXL Investors with Losses in Excess of $100K Have Opportunity to Lead Anavex Life Sciences Corp. Securities Fraud Lawsuit Filed by The Rosen Law Firm
PR Newswire · 10/31 13:45
Russell 2000 estimated to drop 83 stocks in December rebalance - Stephens
Seeking Alpha · 10/29 19:44
AVXL Stockholders Have Rights - If You Lost Money Investing in Anavex Life Sciences Corp. Contact Robbins LLP for Information About Recovering Your Losses
PR Newswire · 10/28 02:34
AVXL Investors Have Opportunity to Lead Anavex Life Sciences Corp. Securities Fraud Lawsuit Filed by The Rosen Law Firm
PR Newswire · 10/26 23:46
What's Next for Anavex Life Sciences Corp. Shareholders After 6.35% Stock Drop? Glancy Prongay Wolke & Rotter LLP Explains Securities Fraud Class Action Lead Plaintiff Deadline
PR Newswire · 10/26 18:00
Weekly Report: what happened at AVXL last week (1019-1023)?
Weekly Report · 10/26 10:00
What Does Anavex Life Sciences Corp.'s 6.35% Stock Drop Mean for Investors? The Law Offices of Howard G. Smith Outlines Securities Fraud Class Action Lead Plaintiff Deadline
PR Newswire · 10/23 17:30
More
Webull provides a variety of real-time AVXL stock news. You can receive the latest news about Anavex Life Scie through multiple platforms. This information may help you make smarter investment decisions.
About AVXL
Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (CNS) diseases with high unmet need. The Company analyzes genomic data from clinical trials to identify biomarkers, which it uses in the analysis of its clinical trials. Its focus is on developing treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other CNS disorders. Its pipeline products include ANAVEX 2-73 (blarcamesine) and ANAVEX 3-7. Its other programs include ANAVEX 1-41, ANAVEX 1066 and ANAVEX 1037. ANAVEX 2-73 is being developed as well as an oral once-daily capsule formulation for diseases such as Alzheimer’s disease and Parkinson’s disease, and in an oral liquid once-daily formulation for rare diseases such as Rett syndrome and Fragile X.